ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.680,20
-0,25%
S&P 500
5.295,08
-0,49%
Dow Jones
39.632,42
-0,60%
Euro vs US Dollar
1,0834
-0,19%
Bitcoin
69.428,10
-1,00%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Aerovate Therapeutics Inc (AVTE)

  7. Aerovate Therapeutics Inc (AVTE) News

AVTE

Aerovate Therapeutics (AVTE)

Aerovate Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AVTE
DatumZeitQuelleÜberschriftSymbolFirma
21/05/202422h15GlobeNewswire Inc.Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceNASDAQ:AVTEAerovate Therapeutics Inc
18/05/202401h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
17/05/202422h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
13/05/202422h57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTEAerovate Therapeutics Inc
13/05/202422h39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTEAerovate Therapeutics Inc
13/05/202422h30GlobeNewswire Inc.Aerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsNASDAQ:AVTEAerovate Therapeutics Inc
27/03/202414h20GlobeNewswire Inc.Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceNASDAQ:AVTEAerovate Therapeutics Inc
25/03/202421h10GlobeNewswire Inc.Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsNASDAQ:AVTEAerovate Therapeutics Inc
11/03/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
07/03/202422h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
06/03/202414h00GlobeNewswire Inc.Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board ChairNASDAQ:AVTEAerovate Therapeutics Inc
28/02/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
23/02/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
21/02/202400h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
09/02/202422h28Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
17/01/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
08/01/202423h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTEAerovate Therapeutics Inc
08/01/202413h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTEAerovate Therapeutics Inc
30/12/202300h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
27/12/202323h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
23/12/202300h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
20/12/202322h24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
16/12/202300h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
14/12/202322h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
08/12/202300h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
30/11/202300h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AVTE

Kürzlich von Ihnen besucht

COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
CCOM
US500
US 500
USOTC
BNPQY
BNP Paribas (QX)
USOTC
ADDYY
Adidas (QX)
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MCD
McDonalds
COIN
BTCUSD
Bitcoin
TG
BAYN
Bayer
CCOM
SILVER
SILVER
TG
TUI1
Tui
NASDAQ
QQQ
Invesco QQQ Trust Series 1
DBI
MDAX
MDAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten